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Abstract
Background Targeted gene transduction in vivo is the ultimate preferred
method for gene delivery. We previously developed targeting lentiviral
vectors that specifically recognize cell surface molecules with conjugated
antibodies and mediate targeted gene transduction both in vitro and in vivo.
Although effective in some experimental settings, the conjugation of virus
with antibodies is mediated by the interaction between protein A and the Fc
region of antibodies, which is not as stable as covalent conjugation. We have
now developed a more stable conjugation strategy utilizing the interaction
between avidin and biotin.
Methods We inserted the biotin-adaptor-peptide, which was biotinylated by
secretory biotin ligase at specific sites, into our targeting envelope proteins,
enabling conjugation of the pseudotyped virus with avidin, streptavidin or
neutravidin.
Results When conjugated with avidin-antibody fusion proteins or the
complex of avidin and biotinylated targeting molecules, the vectors could
mediate specific transduction to targeted cells recognized by the targeting
molecules. When conjugated with streptavidin-coated magnetic beads,
transduction by the vectors was targeted to the locations of magnets.
Conclusions This targeting vector system can be used for broad applications
of targeted gene transduction using biotinylated targeting molecules or
targeting molecules fused with avidin. Copyright  2009 John Wiley &
Sons, Ltd.
Keywords biotin adaptor peptide; endothelial cells; lentiviral vector; Sindbis
virus envelope; targeting vector
Introduction
Retroviral vectors integrate their transgenes into host cell chromosomes,
allowing sustained transgene expression, which is favorable for therapy
of chronic diseases such as congenital genetic deficiencies and chronic
acquired infectious and malignant diseases [1]. Gene therapy using retro-
viral vectors has been shown to be an effective approach for several genetic
diseases such as X-linked severe combined immunodeficiency (SCID) [2,3].
In the case of hematopoietic diseases, such as X-linked SCID, the cells to
be transduced are hematopoietic, which can be easily isolated from the
body, transduced in vitro, and infused back into the body without losing
their physiological functions. However, ex vivo transduction is not suit-
able for gene transduction of solid organs or most body tissues. An ideal
method for gene transduction of solid organs, including tumor tissues, is
Copyright  2009 John Wiley & Sons, Ltd.
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intravenous administration of gene therapy vectors that
specifically home in on and transduce desired cells and
tissues in vivo. Such vectors are referred to as ‘targeting
vectors’, and the development of effective targeting
vectors has been one of the most important issues of
gene therapy [4].
Because retroviral vectors are one of the most useful
types of gene therapy vectors, many research groups
have attempted to create targeting retroviral vectors.
One approach is pseudotyping retroviral vectors with
chimeric proteins generated between retroviral envelope
proteins and targeting molecules, such as single-chain
antibodies or growth factors [5–12]. Another approach is
conjugating virus with adaptor molecules that specifically
recognize desired molecules [13,14]. Each approach has
its own advantages and disadvantages. The targeting
molecules in the first approach are covalently conjugated
to the viral envelope proteins; therefore, conjugation of
these molecules is very stable. However, it is necessary to
generate new chimeric envelope proteins for each target
molecule, and insertion of targeting molecules sometimes
destroys the functions and structures of chimeric proteins.
The second approach does not require generating new
envelope proteins for each target molecule. However,
conjugation between virus and adaptor molecules must
be of very high affinity and stability to maintain
conjugation, especially for in vivo usage. Previously, we
have developed targeting retroviral vectors, both lentiviral
and oncoretroviral, using the second approach [15–18].
These targeting vectors were conjugated with monoclonal
antibodies via the interaction between the Fc-binding
region of protein A (ZZ domain) inserted into the
envelope protein and the Fc region of antibodies. This
targeting system is effective in vitro and in some in vivo
experimental settings that do not require highly stable
conjugation. However, conjugation between the virus
and antibodies may not be sufficiently stable in immune
competent animals because serum immunoglobulin will
compete with conjugated antibodies for binding to
the ZZ domain of the envelope protein [19]. Binding
between avidin and biotin is of very high affinity. The
dissociation constant (Kd) of binding between these two
molecules is 10−15, which is 107–8 less than the Kd
of the binding between the ZZ domain and the Fc
region of antibodies [20]. Several studies have used
this interaction to conjugate adenovirus, adeno-associated
virus and baculovirus vectors with targeting molecules
[21–25]. They inserted peptides, which are substrates
for biotinylation, into structural proteins of adenovirus,
adeno-associated virus and baculovirus vectors, and
the biotinylated sites bound avidin, neutravidin or
streptavidin. Because avidin, neutravidin and streptavidin
forms tetramers, and each tetramer has four biotin-
binding sites, these molecules can bridge between
bitotinylated virus and biotinylated targeting molecules.
By conjugating a wide variety of biotinylated molecules,
these vectors bound to targeted cell surface molecules and
transduced the cells expressing those target molecules.
Although particularly effective in in vitro experimental
settings, these adenoviral and adeno-associated virus
vectors still retain their original native tropism, resulting
in transduction of a wide variety of cell types, regardless
of the expression of targeted molecules and trapping in
untargeted organs before reaching the target cells and
tissues [26–28].
We abrogated the native tropisms of our targeting
lentiviral vectors, resulting in less trapping, especially in
the liver and spleen. The targeting vectors recognized
a target molecule in vivo, and mediated specific gene
transduction to target cells via the interaction between a
conjugated antibody and a target cell surface antigen.
To stabilize the conjugation between targeting
molecules and virus in the presence of serum
immunoglobin, we used the avidin–biotin interaction
to conjugate targeting molecules to lentivirus vectors.
Instead of the ZZ domain, we inserted the biotin-adaptor-
peptide (BAP) into our targeting envelope protein, allow-
ing biotinylation of the envelope protein at specific sites
[29]. The biotinylated envelope proteins were conjugated
with targeting molecules via its interaction with avidin





2.2 1L1L was constructed from 2.2 by replacing the ZZ
domain in the E2 protein with two sets of flexible linker
peptides (GGGGS) X2. BAP SINDBIS was constructed by
inserting BAP between the two flexible linkers of 2.2
1L1L. BBAPH SINDBIS was constructed by inserting BAP
into the junction region of the E3 and E2 proteins of
2.2 1L1L. BAP II SINDBIS was constructed from BAP
SINDBIS and BBAPH SINDBIS by combining the BAP
insertion of each construct into one construct. Therefore,
BAP II SINDBIS contains two BAP insertions at amino
acid position 70 of E2 and the junction between E3
and E2. The expression vector of biotin ligase, pBirA,
was provided by Dr Michael Barry (Baylor College
of Medicine, Houston, TX, USA). The fusion proteins
between avidin and anti-rat [anti-rat transferrin receptor
(TfR) immunoglobulin (Ig)G3-Av] or human (anti-huTfR
IgG3-Av) transferrin receptors were prepared as described
previously [30,31]. Neutravidin was purchased from
Pierce (Rockford, IL, USA). Biotinylated transferrin was
purchased from Molecular Probes (Eugene, OR, USA).
Anti-rat and human transferrin receptor antibodies were
purchased from BD Bioscience (Bedford, MA, USA).
Cells and viruses
293T cells were cultured in IMDM (Sigma-Aldrich, St
Louis, MO, USA) containing 10% fetal calf serum (FCS)
and antibiotics. Jurkat and Y3-Ag1.2.3 cells were cultured
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in RPMI (Invitrogen, Carlsbad, CA, USA) containing
10% FCS. All lentiviral vectors were produced in
293T cells, using the calcium phosphate transfection
method as described previously [15]. Briefly, 293T
cells (1.8 × 107) were transfected with one of envelope
protein expression vectors (10 µg), packaging plasmid,
8.2 delta VPR (12.5 µg), either lentiviral vector, cppt2e
[16] or FuhLucW [17] (12.5 µg) and 6 µg of pSec BirA.
After transfection, the cells were cultured in Opti-MEM
(Invitrogen) containing 2% FCS and 500 mM of biotin.
The supernatant was subjected to ultracentrifugation,
and the pellet containing the virus was resuspended
in Hepes-buffered saline. The resuspended virus was
dialysed in phosphate-buffered saline (PBS) for 4 h to
eliminate residual biotin. The concentrations of virus
were quantified by measuring amounts of viral capsid
protein, p24. The dialysed virus was frozen at −70 ◦C
until use.
The viruses (40 ng p24) were conjugated with anti-
ratTfR IgG3-Av (5 µg) or anti-huTfR IgG3-Av (5 µg) for
30 min on ice before infection. Jurkat or Y3-Ag1.2.3 cells
(5 × 104) were incubated with the viruses for 2 h at
37 ◦C, and then the viruses were washed away. Enhanced
green fluorescent protein (EGFP) transgene expression
was analysed by flow cytometry 3 and 10 days post-
transduction.
BAP II SINDBIS pesudotype (40 ng p24) was incubated
with neutravidin (2 µg) for 30 min, then incubated with
biotinylated transferrin (2 µg). Jurkat cells (5 × 104)
were incubated with the virus for 2 h. Firefly luciferase
transgene expression was assayed by a luminometer
3 days post-infection.
Flow cytometric analysis of transferrin
receptor 1 expression on Jurkat and Y3
cells
Jurkat and Y3 cells (5 × 105) were incubated with 100 µl
(5 µg/ml) of either mouse anti-rat transferrin receptor
1 (BD Biosciences, San Diego, CA, USA) or mouse anti-
human transferrin receptor 1 (BD Biosciences) for 1 h
at 4 ◦C, followed by incubation with 100 µl (200-fold
dilution in PBS) of rabbit anti-mouse IgG conjugated with
Alexa 488 (Invitrogen) for 1 h at 4 ◦C. Antibody staining
was analysed by flow cytometry.
Western blotting
The amounts of viral vectors were normalized to the
amount of HIV p24 (1 mg/ml). The viral vectors were
mixed with same volume of electrophoresis loading
buffer [20% glycerol, 10% 2-mercaptoethanol, 4%
sodium dodecyl sulfate (SDS), 125 mM Tris-HCl (pH
6.8), 0.02% bromophenol blue] and boiled for 5 min.
Each sample (15 µl) was subjected to electrophoresis
through a SDS 4–20% polyacrylamide gel (Lonza,
Rockland, ME, USA). Immunoblot analyses of envelope
proteins were performed with rabbit anti-Sindbis virus
polyclonal antibody (kindly provided by Dr John M.
Polo, Chiron Vaccines, Emeryville, CA, USA) and
horseradish peroxidase (HRP)-conjugated goat anti-rabbit
polyclonal antibody (Pierce). Biotinylation of envelope
proteins was analysed using HRP-conjugated neutravidin
(Pierce). The protein bands were visualized by enhanced
chemiluminescence (Pierce).
Quantitative analysis of biotinylation
of lentiviral vectors
Purified viral vectors (0.5 and 1 µg of p24) were incubated
either with 100 µl of magnet beads conjugated with
streptavidin (Pierce), or these beads incubated with
an excess amount of biotin for 2 h at 4 ◦C. The beads
were then removed using magnets. The amounts of the
viral vectors after magnet subtraction were quantified by
enzyme-linked immunosorbent assay.
Transduction with BAP II SINDBIS
pseudotypes conjugated with
streptavidin-coated magnet beads
Human microvascular endothelial cells (HMVEC) were
provided by Dr Benhur Lee (UCLA, Los Angeles, CA,
USA) and cultured in EBM-2 medium supplemented
with EGM-2 (Lonza). HMVEC (8 × 104 cells) were
seeded in a chamber slide (Nalge Nunc Intetnational,
Naperville, IL, USA) 1 day prior to transduction. BAP
II SINDBIS pseudotype (400 ng p24) was incubated
with 10 µl of streptavidin-coated magnet beads for 1 h
at room temperature. The unbound virus was washed
away three times, using a magnetic particle concentrator
and PBS (Invitrogen). The magnet of the magnetic
particle concentrator was placed under the chamber
slides containing cultured HMVEC. The virus conjugated
with the beads (resuspended in 2 ml of PBS containing
calcium and magnesium) was added to the cells in the
chamber with or without application of the magnet.
Magnet-conjugated viruses were incubated with HMVEC
for various time periods (10 s, 1 and 10 min, and 1 h) with
application of a magnet. EGFP expression was analysed 4
and 10 days post-transduction.
Results
Construction of targeting envelope
proteins with insertion of BAP
We inserted BAP into our targeting envelope protein, 2.2,
instead of the ZZ domain of protein A. The 2.2 envelope
protein is derived from the Sindbis virus envelope protein,
into which the ZZ domain was inserted into its original
receptor-binding region [15], and contains mutations
to eliminate its original tropism [17] and to increase
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infectivity for target cells [16]. To maintain the entire
structure of the envelope protein after insertion of BAP,
we inserted two flexible linkers, which consisted of four
glycine and one serine, at the site of BAP insertion,
designated 2.2 1L1L (Figure 1). The envelope protein
with insertion of BAP was designated BAP SINDBIS. BAP
SINDBIS was used to pseudotype a lentiviral vector, and
expression of the envelope was analysed by western
blotting (Figure 2a), using anti-Sindbis virus antibody.
The lower band is E1 and the upper band is E2 fused with
E3 and into which the linker is inserted. In the case of
BAP SINDBIS, a higher molecular mass band of 64 kDa
represents the E2/E3 BAP fusion protein.
To investigate biotinylation of the inserted BAP,
we performed western blotting and immunostaining
with streptavidin conjugated with HRP (Figure 2b).
BAP SINDBIS was barely biotinylated in the conditions
Figure 1. (a) Schematic representation of chimeric Sindbis virus
envelope proteins. 2.2 1L1L was derived from the chimeric
2.2 envelope protein [18]. 2.2 1L1L has two flexible linkers
(Gly-Gly-Gly-Gly-Ser) and AVR II-Bst E II cloning sites at amino
acid 71 of the E2 protein. BAP Sindbis contains a biotin
acceptor peptide (BAP) derived from Escherichia coli biotin
holoenzyme synthetase between the two flexible linkers. BBAPH
contains BAP at the first amino acid of the E2 protein, and
BAP II SINDBIS contains two BAP at both positions of the
E2 protein. (b) The schematic strategy to conjugate virus with
anti-human or rat transferrin receptor 1 and transferrin. BAP
II SINDBIS envelope proteins were covalently conjugated with
biotin. Anti-human or rat transferrin receptor antibodies were
fused with avidin, designated anti-huTfR IgG-Av or anti-ratTfR
IgG3-Av, respectively. Anti-huTfR IgG-Av or anti-ratTfR IgG3-Av
can be conjugated with the BAP II SINDBIS envelope protein
through the interaction of avidin and the biotin of the envelope
protein. Neutravidin has four biotin binding sites. Thus, one
neutravidin can bind both the biotinylated BAP II SINDBIS
envelope protein and biotinlynated transferrin, which results
in bridging the pseudotyped virus with transferrin
Figure 2. SDS-polyacrylamide gel electrophoresis and western
blotting analysis of chimeric Sindbis virus envelope proteins.
Lentiviral vectors pseudotyped with 2.2 1L1L or BAP SINDBIS,
produced in the presence or absence of pSec BirA and biotin
(500 mM), were analysed using: (a) rabbit anti-Sindbis virus
antibody and goat anti-rabbit IgG antibody conjugated with
horseradish peroxidase; or (b) neutravidin conjugated with
horseradish proxidase. Lentiviral vectors pseudotyped with
2.2 1L1L, BAP SINDBIS, BBAPH SINDBIS, or BAP II SINDBIS,
produced in the presence of pSec BirA and biotin, were analysed
using: (c) rabbit anti-Sindbis virus antibody and goat anti-rabbit
IgG antibody conjugated with horseradish peroxidase; or
(d) neutravidin conjugated with horseradish peroxidase
previously described for production of 2.2 pseudotypes.
Both secreted biotin ligase and adequate amounts of biotin
in culture medium are required for efficient biotinylation
of secretory proteins and viral envelope proteins [29].
Therefore, to enhance the biotinylation of BAP, we
generated BAP SINDBIS pseudotypes in the presence
of secreted biotin ligase and greater amounts of biotin
in culture medium. Under these conditions, the BAP
SINDBIS protein was biotinylated, which is consistent
with a previous study [29] (Figure 2b).
To further increase the efficiency of biotinylation of
the targeting envelope, we inserted an additional BAP
into the envelope protein. We previously found that
the site between the E2 and E3 proteins serves as a
receptor-binding site, and other studies have successfully
inserted targeting molecules into this site [32]. We
therefore inserted BAP into this site, and designated the
envelope BBAPH SINDBIS (Figure 1a). BBAPH SINDBIS
was expressed, pseudotyped with a lentiviral vector,
and was shown to be biotinylated as efficiently as BAP
SINDBIS (Figures 2c and 2d). Accordingly, we created
two BAP insertions in one envelope, one at the junction
between E2 and E3 and the other at the same location
as the ZZ domain. The combined envelope protein
was designated BAP II SINDBIS (Figure 1a). BAP II
SINDBIS envelope had the expected molecular mass in
western blot analysis, and expressed and pseudotyped
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a lentiviral vector as efficiently as single BAP insertions
(Figure 2d). As expected, streptavidin-HRP bound BAP
II SINDBIS more than the single BAP insertions into
envelopes, such as BAP SINDBIS and BBAPH SINDBIS
(Figure 2d). We also investigated the percentage of virions
bearing biotinylation of BAP II SINDBIS pseudotypes using
streptavidin-coated magnetic beads, followed by panning
with magnets. Using this method, the percentages of
the virus subtracted by magnets would represent the
minimum percentage of virus bearing biotinylation.
Streptavidin-coated beads pre-bound with saturating
amounts of biotin were used as a negative control for
virus subtraction. The majority of virus (90%) was shown
to bind to streptavidin-coated beads (Table 1).
Targeted infection with virion-
conjugated targeting molecules
We tested the utility of the biotin/avidin targeting
strategy by using human and rat transferrin receptor
1 as our target for virus binding (Figure 1b). The
targeting ligands were a fusion between avidin and
anti-human transferrin receptor 1 antibody, designated
Figure 3. Gene transduction mediated by fusion proteins between avidin and anti-human or transferrin receptor antibody fusion
proteins. (a) Expression of human and rat transferrin receptor 1 on Jurkat (human T-cell line) and Y3 (rat myeloma cell line) cells.
Each cell type was stained either with isotype control control antibody (black line), mouse anti-human (red line), or rat (blue line)
transferrin receptor 1 antibody, followed by staining with Alexa 488-conjugated secondary antibody. (b) Jurkat, was infected with
the BAP II SINDBIS pseudotype in the presence or absence of fusion protein between avidin and either anti-human (anti-huTfR
IgG-Av) or anti-rat (anti-ratTfR IgG3-Av) transferrin receptor 1 antibody. EGFP expression was analysed by flow cytometry 3 and
10 days post-transduction. Representive flow cutometric profiles are shown. Percent EGFP-positive is shown as the mean ± SD of
triplicate experiments. (c) Y3-Ag 1.2.3, was infected with the BAP II pseudotype in the presence or absence of anti-huTfR IgG-Av
or anti-ratTfR IgG3-Av. EGFP expression was analysed by flow cytometry 3 and 10 days post-transduction. Representive flow
cutometric profiles are shown. Percent EGFP-positive is shown as the mean ± SD of triplicate experiments
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Table 1. Percentage of biotinylated virus







1000 948 33 915 91
500 480 30 450 90
aTotal virus is the amount of virus (ng HIV p24) subjected to binding with 100 µl of streptavidin (StAv)-conjugated magnetic beads.
bVirus bound to StAv-magnetic beads (ng HIV p24) is calculated as: total virus amounta minus amount of remaining virus of in
sample incubated with StAv-magnet. cVirus bound to StAv-magnetic beads pre-treated with biotin (ng HIV p24) is calculated as: total
virus amounta minus amount of unbound virus in sample incubated with biotin-saturated StAv magnetic beads. dBound virus via
StAv–biotin interaction (ng HIV p. 24) is calculated as: amount of virus bound to StAv-magnetic beadsb minus amount of virus bound
to StAv-magnetic beads after pre-treatment with biotinc. eThe minimum percentage of biotinylated virus is calculated as: (amount of
bound virus in the StAv–biotin interactiond divided by amount of total virusa) × 100.
anti-huTfR IgG3-Av, and a fusion between avidin and
anti-rat transferrin receptor 1 antibody, designated anti-
ratTfR IgG3-Av [30,31]. Because the human and rat
transferrin receptor antibodies do not cross react with
the heterologous species, these reagents also allow us
to test specificity of targeting (Figure 3a). Either anti-
huTfR IgG3-Av or anti-ratTfR IgG3-Av was conjugated
with a BAP II SINDBIS pseudotype, and cells expressing
human or rat transferrin receptor 1 were infected with
these viruses (Figures 3b and 3c). Human Jurkat cells
were transduced with conjugates of anti-huTfR IgG3-
Av and not with conjugates of anti-ratTfR IgG3-Av.
The reciprocal patterns were observed when rat Y3-
Ag1.2.3. cells were used as the target. The expression
levels of EGFP did not differ 10 days post-transduction,
eliminating the possibility of pseudo-transduction and
expression from unintegrated vectors. The titers of
BAPII pseudotypes conjugated with anti-human or rat
transferrin receptor-avidin fusion protein are 2 × 105
and 6 × 104 EGFP-transducing units/1 µg HIV p24. These
results demonstrated that infection with BAP II SINDBIS
pesudotypes conjugated with targeting molecules was
specifically mediated by the interactions between the
conjugated targeting molecules and targeted molecules
on cells.
We next attempted to conjugate ligands with BAP II
SINDBIS pseudotypes by using neutravidin to bridge BAP-
containing viruses and biotinylated ligands molecules
(Figure 2b). Because avidin has four biotin-binding
sites, avidin can bridge four biotinylated molecules. We
incubated the BAP II SINDBIS pseudotyped virus with
neutravidin, an avidin derivative with lower nonspecific
binding as a result of mutations at charged amino acid and
N-glycan residues, followed by incubation with chemically
biotinylated transferrin [33]. The conjugated biotinylated
transferrin increased the transduction of BAP II SINDBIS
pseudotypes for Jurkat cells (Figure 4), demonstrating
that the bridged molecules can mediate the binding and
transduction by BAP II SINDBIS pseudotypes.
Targeting BAP II SINDBIS pseudotypes
by magnetic force
Because BAP II SINDBIS pseudotypes can bind
streptavidin-coated magnetic beads, we hypothesized that
Figure 4. Gene transduction mediated by biotinylated transfer-
rin. Jurkat cells were transduced with BAP II SINDBIS pseudo-
type either without conjugation, conjugated with neutravidin, or
conjugated with neutravidin and biotinylated transferrin. Firefly
luciferase was used as a reporter gene, and gene transduction
was analysed by measuring the relative luciferase units (RLU)
of transduced cells. Representative data of three independent
experiments are shown
magnetic force could be used to control the distribution
of viruses. HMVEC in chamber slides, under which a mag-
net was attached, were infected with BAP II SINDBIS
pseudotypes conjugated with streptavidin-coated mag-
netic beads. Expression of the transgene, EGFP, was
visualized with a fluorescent microscope. As shown in
Figure 5a, transgene expression was drastically increased
in a localized area with application of a magnet force. This
increase in transduction was confirmed by flow cytometry
(Figure 5b). HMVEC in the magnetized area transduced
preferentially and almost all cells in the center of the
magnetic field were transduced. We attempted to opti-
mize the incubation time of the magnet-conjugated virus
with target cells (Figure 5c). We incubated the cells with
magnet-conjugated virus for 10 s, 1 and 10 min, and 1 h.
We found that incubation for 10 s is sufficient to obtain
maximal transduction efficiency. The levels of transgene
expression did not decrease 10 days post-transduction
and no obvious cytotoxicity was observed during this
culture period.
These results successfully demonstrate targeting via a
magnetic force.
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Figure 5. Gene transduction mediated by magnetic force. (a) HMVEC cultured in slide chambers with or without a magnet applied
underneath were infected with viruses conjugated with streptavidin-coated magnet beads. EGFP expression was analysed by a
fluorescent microscope at low (×7.5) and high (×63) magnification. The magnet was placed in the area indicated by the white
dotted line. (b) EGFP expression was analysed by flow cytometry. (c) The effect of incubation time of magnet-conjugated virus with
HMVEC on transduction efficiency. Magnet-conjugated viruses were incubated with HMVEC for a variety of time periods (10 s, 1
and 10 min, and 1 h) with application of a magnet. EGFP expression was analysed 4 days post-transduction. Percent EGFP-positive
is shown as the mean ± SD of triplicate experiments
Discussion
The successful application of gene therapy would
be greatly accelerated through the development of
effective and specific vectors that can target and express
therapeutic molecules and/or genes to specified cells,
tissues and organs. We previously developed a targeting
lentiviral vector, which, for the first time, allowed effective
targeting through intravenous injection. A number of
modifications to the pseudotype Sindbis virus envelope
were necessary to maintain infectivity at the same
time as decreasing nonspecific transduction through
utilization of the native Sindbis virus receptors. This
vector construct relied upon an embedded ZZ domain
in the Sindbis envelope to conjugate with antibodies
directed to specific cell surface molecules. However, the
use of antibody conjugates limits application because
serum immunoglobulin in immunocompetent animals can
compete for binding of the target specific antibodies to
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the virions. In the present study, we took advantage of the
high affinity between avidin and biotin to create targeting
vectors that are not limited by potential competition
with serum immunoglobulin. To achieve biotinylation
of the virus, we introduced the bacterial BAP peptide
into the Sindbis envelope. Biotinylation occurred during
production of virus from cells and the biotinylated
vector was then utilized to conjugate with avidin
fusion molecules. We demonstrated the effectiveness
and specificity of this technique using human and rat
transferrin receptors as target cell surface molecules.
One further modification of the conjugates with avidin
fusion proteins was to use avidin as a bridge between
biotinylated virus and biotinylated ligands. Targeting
vector was generated using a ‘sandwich’ technique,
whereby neutravidin, a mutant form of avidin, was used
to bridge between biotinylated virus and biotinylated
ligand. One advantage of such an approach is to facilitate
the formation of conjugates with the appropriate ligand
in that the laborious construction of chimeric fusion
molecules between avidin and the ligand molecule is not
required. The ligands could simply be biotinylated and
utilized with avidin as a bridge. We utilized neutravidin,
a mutant form of avidin, bearing point mutations at
N-glycan residues and charged amino acids [33]. This
mutant form of avidin was shown to have less nonspecific
interactions with charged cell surface molecules, such
as heparan sulfate, as well as lectins present on many
cell types that can interact with N-glycans. Because each
ligand molecule is likely to have its own structural
properties, the choice of whether to construct a fusion
molecule or bridge with neutravidin is likely to depend
empirically upon the nature of the ligand, the stability
of the conjugates, and the transduction efficiency of the
resulting virions.
One novel application of this targeting vector is the
ability to utilize commercially available streptavidin-
coated magnetic beads to form viral conjugates, which can
then be directed with a magnetic field. There have been
reports of clinical applications using magnets to direct
chemotherapeutic reagents to liver tumors [34]. Other
studies have utilized magnetic force to draw magnetic
nanoparticle-loaded endothelial cells to the surface of
steel stents transplanted in rat carotid arteries [35].
Another group delivered magnetic aerosol droplets to
the lungs of mice, using an external magnetic field.
Both studies demonstrated successful targeting [36].
Viruses and their components were also utilized for
magnet-assisted targeted gene delivery in vivo. Iron oxide
nanoparticles coated with hemagglutinating virus of
Japan envelopes were targeted to the brains of mice
by placing magnets on their heads [37]. Adenoviral
vectors associated with magnetic nanoparticles were
also successfully used to transduce to the stomachs of
mice when an external magnetic field was applied to
the stomach area [38]. Because these viruses and their
components maintain their original tropisms, systemic
injection of such vectors could still transduce untargeted
organs [21,27,38]. Applications of magnetic targeting by
viral vectors will be facilitated if the original tropisms
of vectors are abrogated. The appropriate placement of a
magnetic field could direct a targeting vector to a localized
organ within the body.
The development of specific targeting vectors would
facilitate the application of gene therapy for many
diseases. In the future, targeting vectors that home to
specific cells would allow earlier therapeutic intervention
in the case of progressive diseases, such as cancer [39],
or perhaps target residual cells in chronic and latent
infections by infectious agents, such as HIV-1. The use
of targeting vectors enhances safety of gene therapy by
restricting the number of cells to only those that require
therapeutic intervention [40]. The refinements described
in the present study extend the utility of targeting vectors
beyond that which we previously reported utilizing
antibody conjugates. Further enhancements eventually
may allow us to achieve our goal of specific targeting to
localized tissues in order to effectively treat that disease
within a diseased individual.
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